EFX
32
2
IBM
54
4
PSA
51
-4
AXP
66
2
URI
53
-2
DNB
78
6
BEN
45
3
APA
21
2
AES
39
-4
FLS
73
-2
ETR
68
3
HON
65
-2
EXPE
88
2
GRMN
62
-3
T
50
3
C
58
-2
IR
63
3
CSCO
63
2
EOG
58
2
AMAT
36
5
EFX
32
2
IBM
54
4
PSA
51
-4
AXP
66
2
URI
53
-2
DNB
78
6
BEN
45
3
APA
21
2
AES
39
-4
FLS
73
-2
ETR
68
3
HON
65
-2
EXPE
88
2
GRMN
62
-3
T
50
3
C
58
-2
IR
63
3
CSCO
63
2
EOG
58
2
AMAT
36
5
Financhill
Back

Revance Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
10

RVNC
Revance Therapeutics

Last Price:
3.84
Seasonality Move:
2.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Revance Therapeutics Price Quote

$3.84
+0.04 (+1.05%)
(Updated: November 21, 2024 at 5:55 PM ET)

Revance Therapeutics Key Stats

Sell
10
Revance Therapeutics (RVNC) is a Sell
Day range:
$3.76 - $3.88
52-week range:
$2.30 - $9.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.50
P/B ratio:
0%
Volume:
1.5M
Avg. volume:
2.3M
1-year change:
-49.1%
Market cap:
$418.6M
Revenue:
$234M
EPS:
$-1.94

How Much Does Revance Therapeutics Make?

Is Revance Therapeutics Growing As A Company?

  • What Is Revance Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.11%
  • What Is Revance Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Revance Therapeutics Stock Price Performance

What Is Revance Therapeutics 52-Week High & Low?

Revance Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Revance Therapeutics?

Is Revance Therapeutics Cash Flow Positive?

  • What Is RVNC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$190.9M
  • What Is Revance Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $81.7M
  • What Is Revance Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$12.9M

Revance Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    RVNC return on invested capital is -61.49%
  • What Is Revance Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -37.25%
  • What Is RVNC Return On Equity?
    ROE is a measure of profitability and is 0%

Revance Therapeutics Earnings Date & Stock Price

Revance Therapeutics Competitors

Revance Therapeutics Dividend Yield

Revance Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 6.33%
Revenue: 10.66% -12.17%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 8
Sell Recommendations: 0
Price Target: 9.23
Upside from Last Price: 142.78%

Major Shareholders

  • How many RVNC shares are owned by institutional investors?
    110.2M RVNC shares are owned by institutional investors
  • How many RVNC shares are owned by insiders?
    2.7M RVNC shares are owned by insiders